Human CYP2C19 Gene Polymorphism Detection Kit

PCR-Fluorescence Probe - Clopidogrel Medication Guidancea)


a) Clinical UseClopidogrel (Plavix) is an oral antiplatelet drug that can be used to prevent and treat myocardial infarction, ischemic cerebral thrombosis, occlusive vasculitis, atherosclerosis and thromboembolism caused complications. However, Clopidogrel must be biologically converted in the body into an active product to inhibit platelets’ aggregation. This biotransformation process requires cytochrome P450 encoded by the CYP2C19 gene in the liver metabolism, and the active product can selectively and irreversibly block the diphosphate adenosine-dependent platelet aggregation. The CYP2C19 gene loci alleles 681, 636 and -806 Clopidogrel metabolic enzymes are closely related to its anticoagulant effect, and Clopidogrel dose varies significantly among different patients’ genotype.


The study confirmed that CYP2C19 gene wild type CYP2C19*1/*1 type, CYP2C19*2 type, CYP2C19*3 type and CYP2C19*17 are the Chinese population more common alleles, of which CYP2C19*2 and CYP2C19*3 types can cause CYP2C19 gene encoding enzyme activity loss, carriers are called weak metabolizers. The CYP2C19*17 type can cause CYP2C19 gene encoding enzyme activity increase, and carriers are called fast metabolizers. In January 2009, Harvard University, Jessica L.M. et al., published the results of clinical research in the New England Journal of Medicine, confirming that the risk of embolism and the incidence of cardio-cerebrovascular events were increased, and the mortality rate was higher when the CYP2C19 gene mutation resulted in weak metabolism individuals. It was necessary to increase the dosage of Clopidogrel to achieve the effect of blocking platelet aggregation. Therefore, the CYP2C19 gene mutation detection has an important clinical significance in Clopidogrel personalized medication realization and cardiovascular diseases mortality rate reduction.


In March 12, 2010 the U.S. Food and Drug Administration (FDA) added a "black box warning to the label of Plavix" alerting patients and doctors about Clopidogrel drug specifications metabolic disorders. Emphasis was placed on the importance and feasibility of controlling the gene detection of Clopidogrel metabolism (CYP2C19) in patients, and the corresponding antiplatelet strategy adjustment.


*Please refer to attached Chart 1

Chart A showed that after Clopidogrel treatment, the mortality rate of cardiovascular events and stroke in patients with CYP2C19 mutation increased by 51% compared with that in the CYP2C19 gene-wild patients.


*Please refer to attached Chart 2

Chart B chart showed that Clopidogrel was routinely administered after percutaneous coronary intervention. Compared with patients with wild-type CYP2C19 gene, the risk of re-embolization in patients with CYP2C19 mutation was increased by more than 2 times.

Source : Jessica L.M. et al. N Eng J Med 2009, 360:354-62.


b) Product Introduction

Objective: Human CYP2C19 Gene Polymorphism assay kit (PCR fluorescent probe method) is used to detect CYP2C19 gene 681, 636, and -806 loci polymorphism in vitro, and to guide Plavix (Clopidogrel Bisulfate) clinical medication.


CYP2C19 Gene Polymorphism


Gene alteration base

Asian population probability

Metabolic type


Wild type


Extensive metabolizers 


681G à A


Intermediate metabolizers 


636G à A


Poor metabolizers 


-806C à T


Ultra-rapid metabolizers 


CYP2C19 Gene Detection



(*1/*1) 45%

        - CYP2C19 gene has no effect on Plavix efficacy.

        - Application of conventional Plavix dose ACS and PCI post-operation (75mg/d).




(*1/*2; *1/*3) 40%

        - Patient